Author Archives: admin


On Holocaust Remembrance Day, the stories of two Jewish scientists – Massive Science

The 2019 novel coronavirus (2019-nCoV) outbreak has sparked a speedy response, with scientists, physicians, and front-line healthcare professionals analyzing data in real-time in order to share findings and call out misinformation. Today, The Lancet published two new peer-reviewed studies: one which found that the new coronavirus is genetically distinct from human SARS and MERS, related viruses which caused their own outbreaks, and a second which reports clinical observations of 99 individuals with 2019-nCoV.

The first cases of the coronavirus outbreak were reported in late December 2019. In this new study, Nanshan Chen and colleagues analyzed available clinical, demographic, and laboratory data for 99 confirmed coronavirus cases at the Wuhan Jinyintan Hospital between Jan 1 to Jan 20, 2020, with clinical outcomes followed until 25th January.

Chen and colleagues reported that the average age of the 99 individuals with 2019-nCoV is around 55.5 years, where 51 have additional chronic conditions, including cardiovascular and cerebrovascular (blood flow to the brain) diseases. Clinical features of the 2019-nCoV include a fever, cough, shortness of breath, headaches, and a sore throat. 17 individuals went on to develop acute respiratory distress syndrome, resulting in death by multiple organ failure in 11 individuals. However, it is important to note here that most of the 2019-nCoV cases were treated with antivirals (75 individuals), antibiotics (70) and oxygen therapy (75), with promising prognoses, where 31 individuals were discharged as of 25th January.

Based on this sample, the study suggests that the 2019 coronavirus is more likely to affect older men already living with chronic conditions but as this study only includes 99 individuals with confirmed cases, it may not present a complete picture of the outbreak. As of right now, there are over 6,000 confirmed coronavirus cases reported, where a total of 126 individuals have recovered, and 133 have died.

In a second Lancet study, Roujian Lu and their fellow colleagues carried out DNA sequencing on samples, obtained from either a throat swab or bronchoalveolar lavage fluids, from eight individuals who had visited the Huanan seafood market in Wuhan, China, and one individual who stayed in a hotel near the market. Upon sequencing the coronaviruss genome, the researchers carried out phylogenetic analysis to narrow down the viruss likely evolutionary origin, and homology modelling to explore the virus receptor-binding properties.

Lu and their fellow colleagues found that the 2019-nCoV genome sequences obtained from the nine patients were very similar (>99.98% similarity). Upon comparing the genome to other coronaviruses (like SARS), the researchers found that the 2019-nCoV is more closely related (~87% similarity) to two bat-derived SARS-like coronaviruses, but does not have as high genetic similarity to known human-infecting coronaviruses, including the SARS-CoV (~79%) orMiddle Eastern Respiratory Syndrome (MERS) CoV (~50%).

The study also found that the 2019-nCoV has a similar receptor-binding structure like that of SARS-CoV, though there are small differences in certain areas. This suggests that like the SARS-CoV, the 2019-nCoV may use the same receptor (called ACE2) to enter cells, though confirmation is still needed.

Finally, phylogenetic analysis found that the 2019-nCoV belongs to the Betacoronavirus family the same category that bat-derived coronaviruses fall into suggesting that bats may indeed be the 2019-nCoV reservoir. However, the researchers note that most bat species are hibernating in late December, and that no bats were being sold at the Huanan seafood market, suggesting that while bats may be the initial host, there may have been a secondary animal species which transmitted the 2019-nCoV between bats and humans.

Its clear that we can expect new findings from the research community in the coming days as scientists attempt to narrow down the source of the 2019-nCoV.

Read the original here:
On Holocaust Remembrance Day, the stories of two Jewish scientists - Massive Science

Lessons Learned on Listening to the Dying, World Cancer Day Reflections – MissionsBox

World Cancer Day 2020 by Karen Burton Mains

Years ago, traveling around the world in the role of a journalist at the invitation of the director of an international relief organization, we stopped to visit Mother Theresas Kalighat Home for the Destitute Dying. I will always remember, as have other journalists before me, particularly Malcolm Muggeridge, the soft light that embraced the building and the unusual peace. The calm in the eyes of the Sisters of Charity. The rows of cots with emaciated bodies on them. Brown eyes looking into the distance. The feeling of being poised at some edge. Mostly, I remember the enfolding light. The light.

By the time our son, Jeremy Mains, was rushed to the local hospitals emergency room, his bone marrow was filled with cancer cells. I noticed that April of 2013 that he had seemed unusually tired, but I chalked it up to holding down several part-time jobs and being a highly involved father of three small children, which entailed sharing home responsibilities with a working wife.

However, when the GP phoned Angela with an urgent message that bloodwork results indicated that Jeremy should go immediately to Central DuPage Hospitals ER, our son had already been admitted, his kidneys shutting down. He was quickly diagnosed as suffering from an acute form of a rare lymphoma. Quickly, he was transferred to the oncology unit of Rush University Medical Center in downtown Chicago.

I wish I had read Atul Gawandes Being Mortal before our son, Jeremy, died at age 41 of acute blastic mantle-cell lymphoma. Gawandes book is subtitled Medicine and What Matters in the End and is a practicing surgeons deeply affecting journey into examining how medicine can do better facilitating the last months, weeks, days and minutes of a patients life.

In order to write about this topic well, Gawande follows a hospice nurse on her rounds, visits with a geriatrician in his clinic and dialogues with people reforming nursing-home practices. Then he interviews patients and the elderly as to how they want to frame their last days. His conclusions are pertinent for all who face end-of-life scenarios, whether through disease or old age.

Gawande writes,

Two-thirds of terminal cancer patients in the Coping With Cancer study reported having no discussion with their doctors about their goals for end-of-life care despite being, on average, just four months for death. But the third who did have discussions were far less likely to undergo cardiopulmonary resuscitation or be put on a ventilator or end up in an intensive care unit. Most of them chose hospice. They suffered less, were physically more capable, and were better able, for a longer period, to interact with others.[1]

At this time, I and a handful of friends, all of us with decades of ministry experience behind us, were testing the concept of listening groups. Eventually, over the course of eight years, I would lead some 250 listening groups, the majority with three to four participants, meeting once a month over seven months. The listening groups were trialed in various other settingsone a weekend retreat with 90 attendees; another, a group of 26 people we took on a tour to France. A pastor friend experimented using the listening-group model with his church staffwith great success, he reported to me. The architecture of the listening groups that my friends and I were testing surprised us with how quickly the group members felt safe with one another.

The format was built around a listening structure that ensured space and time enough for each of the participants to feel not only heard but understood. A gentle discipline maintained that the response to each one who shared could only be in the form of a question, and that could be asked only when the person sharing was finished with what he/she wished to say. This eliminated the distresses many small groups facea dominant personality, for instance, or sermonettes that interrupt the individuals own capacity to analyze and determine their own paths to maturation. We even forbid the well-intended-but-interrupting, Oh, let me pray for you. I watched, often in surprise, at the development of this deepening capacity of the participants to hear and be heard, which appeared to result in measurable and unusually rapid personal growth.

Listening to your son, however, who has been given a diagnosis that most likely will be terminal, is another matter altogether. A dedicated team of oncologists at Rush University Medical Center in Chicago, headed by Dr. Parameswaran Venugopal, the head of the cancer unit (where Jeremy spent practically all of the last few months of his life), designed a strong chemotherapy-and-radiation treatment course with an accompanying pharmaceutical regimen. Our son was young (41 years old) and healthy (once the kidney failure had been reversed). Plus, he was determined to live. Because of all this, there was a slim chance of Jeremy beating the odds.

Rough notes in my quick-scrawl handwritingalmost unreadable even to meindicated that on June 10, in room 1058 of the ICU, Dr. Stephanie Christiansen walked us through the progress of his disease. I wrote in my notebook:

Blastic mantle cell lymphoma. Burkitt cell lymphoma. Blastic = immature white cells. Mass in colon/not typical. STAGE FOUR. Lymphoma.org. Mantle cell is slow growing. Lots of variations. Treatments (1) Chemotherapy/HyperCVac given in cycles of 3 or 4 days, up to 8 cycles. Cycle A drug regimen. Infection. White counts are low[indecipherable word](something?) count every day. Stem cell transfusion.

Perhaps this erratic series of words and phrases gives a sense of how confusing cancer-cell diagnosis and treatment can be to the average family member. Angela, Jeremys wife, was persistent in achieving a laypersons understanding. I tried to grasp what I could, but basically found myself deferring to her determined comprehension.

One day, thinking to myself, If I ever want to write about this, I need to keep better records, I looked over a medical page given us by the hospital staff. The headline was CYTOTOXIC / HAZARDOUS MEDICATION ORDER. At my request, a kind nurse pulled the website description of some of the drugs in Jeremys regimen. She also printed me off a copy of the HyperCVad A regime. The drugs listed were: Aloprim, used for stopping high uric acid levels during chemo; dexamethasone; used to treat leukemia and lymphoma; ondansetron, used to stop upset stomach and throwing up; Mesna, used to lower the bad effects of some cancer drugs on the bladder; doxorubicin, used to treat cancer, leukemia and lymphoma; and Vincristine, used to treat leukemia, lymphoma and cancer. These were only for the beginning stages of Jeremys pharmaceutical regimen.

I wont list all the negative side-effects each individual drug is capable of causing. All the printouts for each drug, often four pages long, however, include this question: What are some side effects that I need to call my doctor about right away? Then in caps: WARNING / CAUTION.

What follows on each page is a list comparable to the TV pharmaceutical ads where a narrator breathlessly races through possible detrimental responses from the drug the advertisement has just touted as a near-miracle cure. This voiceover invariably accompanies a visual montage of happy people being healed of whatever ailment. Or if not a cure, there are, at least, tantalizing promises of renewed health and vigor, well-being (inferred by the smiles and satisfaction on the actors faces) and some physical outcome that is much, much better than the other competitive drug on the market. Inevitably, somewhere in that rushed half-whispered cacophony of possible side effects, the phrase that can possibly result in death usually occur. The truth is this: There is almost no drug you put into your body that wont cause side effects, eventually, of some kind.

In these early days of treatment, Jeremy, with his wry sense of humor, noted that he had been warned that nausea and diarrhea would be side effects of the chemo: But no one told me I would explode from both ends at the same time! That night before this observation he had lain for some time, exhausted, on his hospital bathroom floor before a nurse found him. Chemo treatments are basically a controlled poisoning of the body.

My instinctpurely a personal uninformed lay opinion, most non-scientific to be sure, and one from a mother watching her child die a gruesome deathis this: One day we are going to look back, like we do now on the Greek physician Galens concept of four humors in the blood and the practice of bloodletting and purging and say, You mean they used to treat cancer by poisoning the body? And the treatment was often as dangerous as the disease?! How barbaric! I feel this in my bones (or perhaps I should say in my genes, since at this time gene manipulation is one of the possible cancer-cure frontiers). Still, I bow before the fact that chemotherapy and surgery are curatives for many cancers in many stages, and I understand that the knowledge to cure evolves in countless laboratories, scattered research centers and across the hospital wards of many countries. Sometimes cures take decades, even centuries, to discover.

Somewhere in this first month, Jeremy said to me, Mom, I dont know if I can do this. To my sons private confession of weakness, I shot back, Of course you can. And no wonder I reacted: We were only one month into the horror that is the cancer journey. Despite its ubiquitous presence in our modern world, for the patients and their families who succumb to the diseaseand believe me, this is a family affairwe were all impacted beyond our capacity to absorb and understand. Societal familiarityover 500,000 people die of cancers every year in the U.S.does not translate to personal capability when faced with this diagnosis in your own family.

Instead of my instinctive buck-up retort, I should, instead, have asked those gentle questions drawn from my experience with the listening groups and my consequent research into what happens in the brain when someone feels listening to and understood. I get it. Sometimes I dont know if any of us are going to get through all this. Tell me what youre thinking and what you are feeling.

The battle of being mortal is the battle to maintain the integrity of ones life, writes Dr. Gawande, to avoid becoming so diminished or dissipated or subjugated that who you are becomes disconnected from who you were or who you want to be. Sickness and old age make the struggle hard enough.[2] In every way through those months of hospitalization, I watched my son become diminished and dissipated and subjugated and disconnected. To my great regret, I did not offer my son this opportunity of end-of-life discussions. Though my grief at losing a child was and is still a clean griefthere was no breach in relationship, no sorrows of alienation o displeasure with each otherI do wish I had read Being Mortal before Jeremy died. Gawandes remarkable book was released in 2014; Jeremy died the year before.

So, the team of oncologists, headed by Dr. Venugopal, valiantly designed treatments, the goals of which were to bring the active cancer into remission, to keep the toxicity manageable, and to find a donor for a bone-marrow transplant. Jeremys oldest brother, Randall, was a perfect match, but that life-supporting treatment was not to be.

I watched as the whole hospital system moved in concentrated efficiency to preserve my sons life. Siddhartha Mukherjee, writing about leukemia, captures this medical momentum beautifully in his Pulitzer Prize-winning book The Emperor of All Maladies:

The arrival of a patient with acute leukemia still sends a shiver down the hospitals spineall the way from the cancer wards on its upper floors to the clinical laboratories buried deep in the basement. Its pace, its acuity, its breathtaking, inexorable arc of growth forces rapid, often drastic decisions; it is terrifying to observe, and terrifying to treat. The body invaded by leukemia is pushed to its brittle physiological limitevery system, heart, lung, blood, working at the knife-edge of its performance.[3]

This describes exactly what I observed about the medical teams working around our son.

Jeremy did go into remission, which Dr. Venugopal described to Angela as a miracle. But the treatment was so toxic to his system that he had no capabilities to fight off the highly contagious and antibiotic-resistant staph infection MRSAin medical terminology, Methicillin-resistant Staphylococcus aureusa potential killer for the immune system-deficient. Though present in general society, ironically it particularly loves to lurk in hospitals.

Jeremy succumbed to waves of infection. Ironically, the very PICC line inserted in a vein on his chest closer to his heart so intravenous treatments could be administered was the very source of many of these infections. Soon, Jeremys mouth and face became paralyzed. He couldnt eat, was fed through stomach tubes, his words were bumbled, and in truth, after the chemotherapy treatments, at least to my viewpoint, there was not one day when he was better than the day before.

Nor do I know, apart from Jeremys wife Angela, if any one on that whole oncology team, from nurses, to teaching fellows, to the head of the hematology department, to the social workers, to the visiting pastors, ever talked to Jeremy about what was important to him as far as how he wanted to die. This I do know: Our son basically spent the last five months of his life, going from debilitating physical crisis to demeaning physical incapability, longing to be home with his wife and three small children; Eliana age six, Nehemiah age three and the baby, Anelise, age six months. And he wanted to be home on his own terms, anyway, anyhow.

(Lest I forget, let me also mention the two English Bulldogs, Roxie and dArtagnan, from whom, during his few brief days at home, Jer also refused to be separated.)

Gawande makes it clear that a listening process is paramountone in which sensitive questions are asked of the patient as far as what kind of attention attendants and family should be giving to those near death. (This must be a situation in which the medical profession does not do all the talking, however, but learns to listen and to be patient in the listening processquite a stretch for most knowledgeable folk in any field.) He assesses the deficiencies of retirement and nursing home environments:

This is the consequence of a society that faces the final phase of the human life cycle by trying not to think about it. We end up with institutions that address any number of societal goalsfrom freeing up hospital beds to taking the burdens off families hands to coping with poverty among the elderlybut never the goal that matters to the people who reside in them: how to make life worth living when were weak and frail and cant fend for ourselves.[4]

Being Mortal takes a stunning turn into the personal when the writers father, Atmaram Gawande, a well-respected and successful surgeon himself, succumbs to cancer. The doctor/son realized that with all the research he had conducted on listening to those in end-of-life scenarios, and with all the insights he had achieved, it was most difficult to apply those principles to his own father. His medical training, his save-and-preserve-life mentality swooped in and crowded out empathy, driving him to find a cure, to perform some sort of intervention. Believe me, I understand.

The problem with medicine and the institutions it has spawned for the care of the sick and the old is not that they have had any incorrect view of what makes life significant, Gawande writes.

The problem is that they have had almost no view of it at all. Medicines focus is narrow. Medical professionals concentrate on repair of health, not sustenance of the soul. Yetand this is the painful paradoxwe have decided that they should be the ones who largely define how we live in our waning days This experiment has failed.[5]

The next death we go through as a family, if we have any choice at all, will not be done this way. Our son, brilliant and gifted, a multicultural specialist, an adjunct professor teaching college Spanish and who also was functional in conversational Mandarin, this young man with his own immigration counseling service who had achieved the skills and grasp of a paralegal, this funny and compassionate and intriguing young man, died a gruesome death. I shudder even now as I think about it.

Still, before toxicity blasted his nervous system and his mouth became paralyzed (closed for months, then frozen open before he died), this young man, our son, in the early stages of his own death, taught me to listen to the dying. He determined that the long hours spent on my shift would be devoted to catching me up on my woeful ignorance of popular music, or as his teasing explanation defined it, That would be the last fifty years of music history, Mom. His sly gotcha glance was only made more roguish by his drooping face. My father, after all, had been the director of the music department of Moody Bible Institutehardly a bastion of contemporary cultural musicology. I was raised in a home where the emphasis was onguess what?church music. Worship services. Choir practices on Thursday nights. Youth choir rehearsals on Sunday afternoons. Worship services. Sunday night signs. Candlelight carols. Easter cantatas.

Using his iPad to pull down samples from Pandora, I then realized Jeremy was looking at our study not so much as a pop-culture aficionado but through the understanding of an ethnomusicologist. There was no one I would rather have traveled around the world with as a guide than Jeremy. In high school, he found a native speaker to tutor him in Japanese and took himself off to Japan at age 16 for a summer of foreign culture and a conversational-language plunge. While in college and at his instigation, Jeremy met me at the Art Institute of Chicago to view an exhibit of ancient Japanese kimonos. This private gallery tour gave me a hint that this son was a compulsively curious scholar, a lifelong learner. He knew the styles and ages of the kimonos without looking at the wall plaques. It was here I learned about the Edo period between 1603 and 1868 under the rule of the Tokugawa shogunate, the last military feudal government. I also received an additional short and unasked-for briefing on the demise of the samurai.

Let us next move to China, where Jeremy lived and taught for a cumulative total of three yearstwo years before he and Angela wed and one after. Need to know about the Shang Dynasty? (Approximate duration? 16001000 B.C.). How about the Ming Dynasty? What about the Boxer Rebellion? Before visiting him for a month in the middle of his two-year teaching contract at the Petroleum Institute in the city of Nanchong, Sichuan Province, we were emailed a full reading list to study before embarking. Certainly, it was the equivalent of a college semester of learning.

Jeremy kept records by printing pertinent ideas in small black notebooks, those wrapped with black elastic bands. So, with his determination not to waste the hospital hours, still lying in bed, and with me, a captive student at hand, spending hours, sometimes day and all-night shifts, he introduced me to the American Music Idiom 101. The black books came out, then the iPod. It didnt take me long (probably on a train ride from the Chicago back to the suburbs) to realize I was being privately tutored in a spontaneous course in ethnomusicology. Initially, that was the study anthropologists made of non-Western music and the cultures and environments and customs that gave rise to them. Eventually, attention was turned toward Western music as well. In short, ethnomusicology has been described as the study of people making music. This is exactly what this son opened up for mehe helped me to understand contemporary popular music as a means to identify with the people who had either made or were now making it.

Totally unprepared for the learning curve ahead, seeking at first only to console a gravely ill son, to help assuage the boredom of long hours, to divert attention from the constant tests and blood draws and the impossible difficulty of swallowing pills (even before his mouth became frozen, when kind nurses crushed all the tablets, and even then the taste was so bitter he had difficulty), I began one of the most profound listening experiences of my life. Admittedly, my literacy in popular music consisted of the infrequent songs I heard that others were listening to, or occasional snatches of the tuning dial while drivingthe oldies radio station in Chicago, 94.7. The learning was delightful, and I began to see that much of popular music was a cry from the mean streets, sung evidence, in many cases, of what we faith-based folk consider true lostness; I am deeply grateful for the exposure. I learned to listen to the words and rhythms of another kind of dying in that hospital room of my dying child.

As a result of the early chemo rounds when an Ommaya Reservoir had been implanted in his skull to enable the toxic intrathecal brain drips, and because of this procedure, a bilateral droop developed, paralyzing a side of Jeremys face and his mouth. It became an excruciating exercise to catch what our son was attempting to say since the consonants b, d, f, m, n, p, v and w were unpronounceable. Sometimes Jeremy would actually press his lips together with his fingers to make the puffing effort for any of these sounds.

Of course, if asked, I would have made the decision to give my life for his in an instant. I would have made the decision for this exchange with such fierce love, such terrible tenderness and without a moments hesitation. But that was not a choice at hand for any of us who loved him. But what I could have done I wish I had done. I regret not opening up those conversations about life and its meaning, about death and its coming possibility. If death is facing you, my dear son, how do you want to frame your last days?

There is a curious thing about death, at least for me: The dead are not forgotten. Those we have known in love exist in flashes of vivid understanding after they are gone. My father died when I was 35, my mother when I was 39. The essence of who they were lives on in merarely a day goes by that I dont think of them. I am now in my 70s. We, the living, assess the meaning of the lives of loved ones now dead in ways we would never do had they still been living. We tell remember-when stories, and we often pause to analyze the impact of those family events in a way we do not if participants were still alive. Remember the working trip we took together in the Caribbean? What was your favorite part of the trip to Europe? Do you remember how you took on your dad when we arrived in Beijing? (As Jeremy was bartering with Chinese taxi-drivers at the airport after our long flight from the States, David, weary and jet-lagged protested, Jer, just get a cab, any cab. Jeremy asked, Do you speak Mandarin? Or is it I who speaks Mandarin? Point made.)

I am still processing the meaning of my sons life and of his death. What have I learned from him? What should I change about the way I approach the days aheadthose days of living and the inevitable days of dying? I have learned this muchone lesson among the manyDavid and I are saying to one another, my husband and I, Let us talk together about dying. Let us listen deeply to each other and learn what will make the passage from this world to the next bearable, compassionate and as much as possible for our offspring, considerate.

I do probably have some papillary cancer floating around in the cells of my own body. A cancerous thyroid was removed from my throat five months after Jeremys death. It is a slow-growing cancer. So, my wish at this almost octogenarian age is this: Should that cancer flourish and thrive, let me die. I dont want at this stage to go through the debilities and excruciating treatments of this current time. I have lived a rich and good life. Four beautiful children. Nine delightful grandchildren. A fruitful and meaningful marriage of some 59 years. A circle of friends. A deep and sustaining faith in God and His Son Jesus Christ. Travel to some 55 countries in the world. Board work with crucial faith-based development organization with corporate missions I was proud to serve. The accomplishment of writing twenty-some books.

This, apart from a magical plunge into ethnomusicology, is another of the lessons about dying I learned from a dying son. Living ends. We cannot always determine when or how that will happen. Yet, in small and remarkable ways, we can ready ourselves for that terminal status. We can be clear, apart from the freak and indubitable accidental, about how it is we want to die. That is not a morbid choice, to talk about our own deaths. End-of-life conversations are paramount to passing well. They fit into the Scriptural discourse of the Apostle Paul,

For I am already being poured out like a drink offering, and the time has come for my departure. I have fought the good fight, I have finished the race, I have kept the faith. Now there is in store for me the crown of righteousness, which the Lord, the righteous Judge, will award to me on that dayand not only to me, but also to all who have longed for his appearing. 2 Timothy 4:67.

I miss my son. Miss him every day. But then, I too am close. I am close.

Footnotes:

To read more news on World Cancer Day on Missions Box, go here.

For another blog on Patheos by Karen Burton Mains, go here.

For more blogs on Patheos by Gospel for Asia, go here.

Go here to read the rest:
Lessons Learned on Listening to the Dying, World Cancer Day Reflections - MissionsBox

Spinal injury researchers find a sweet spot for stem cell injections – New Atlas

As they do in many areas of medicine, stem cells hold great potential in treating injured spinal cords, but getting them where they need to go is a delicate undertaking. Scientists at the University of California San Diego (UCSD) are now reporting a breakthrough in this area, demonstrating a new injection technique in mice they say can deliver far larger doses of stem cells and avoid some of the dangers of current approaches.

The research focuses on the use of a type of stem cell known as a neural precursor cell, which can differentiate into different types of neural cells and hold great potential in repairing damaged spines. Currently, these are directly injected into the primary cord of nerve fibers called the spinal parenchyma.

As such, there is an inherent risk of (further) spinal tissue injury or intraparechymal bleeding, says Martin Marsala, professor in the Department of Anesthesiology at UCSD School of Medicine.

In experiments on rodents, Marsala and his team have demonstrated a safer and less invasive approach. The scientists instead injected the stem cells in between a protective layer around the spine called the pial membrane and the superficial layers of the spinal cord, a region known as the spinal subpial space.

This injection technique allows the delivery of high cell numbers from a single injection, says Marsala. Cells with proliferative properties, such as glial progenitors, then migrate into the spinal parenchyma and populate over time in multiple spinal segments as well as the brain stem. Injected cells acquire the functional properties consistent with surrounding host cells.

Following these promising early results, the scientists are hopeful that stem cells injected in this way could one day greatly accelerate healing and improve the strength of cell-replacement therapies for several spinal neurodegenerative disorders, including spinal traumatic injury, amyotrophic lateral sclerosis and multiple sclerosis. But first will come experiments on larger animal models closer to the human anatomy in size, which will help them fine tune their technique for the best results.

The goal is to define the optimal cell dosing and timing of cell delivery after spinal injury, which is associated with the best treatment effect, says Marsala.

The research was published in the journal Stem Cells Translational Medicine.

Source: University of California San Diego

Read the original:
Spinal injury researchers find a sweet spot for stem cell injections - New Atlas

Younger Age, Consolidation Therapy With Autologous SCT Associated With Improved OS in Patients With Primary CNS Lymphoma – Oncology Nurse Advisor

Resultsof a large population-based study of patients with primary CNS lymphoma diagnosedbetween 2011 and 2016 showed a higher proportion of patients 60 years and oldercompared with reports from studies conducted 1 to 2 decades earlier. The findings from this study were published inNeurology.

PrimaryCNS lymphoma is a rare, aggressive form of non-Hodgkin lymphoma that caninvolve the brain, spine, leptomeninges, and eyes. It is characterized by theabsence of systemic disease, and a poor prognosis.

Anumber of advances in the treatment of patients with this disease have beenmade over the past 3 decades. These have included replacement of conventional whole-brainradiotherapy (WBRT) alone with combined modality therapy including high-dosemethotrexate-based chemotherapy followed by WBRT consolidation, which was shownto prolong time to recurrence in these patients. Alternatively, the use of first-line,high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) consolidationis an approach designed to circumvent WBRT-associated toxicity.

Inaddition, studies of the safety and efficacy of combining first-line high-dosemethotrexate with other drugs, such as high-dose cytarabine or rituximab, haveshown promising results, although concerns related to toxicity, particularly inolder patients, remain with some of these approaches.

Thisretrospective study included patient-, disease-, and treatment-related data forall adult, HIV-negative patients with primary CNS lymphoma diagnosed between2011 and 2016 who were included in the French oculo-cerebral lymphoma network,a prospective, nationwide database.

Ofthe 1002 patients included in this analysis, the median patient age was 68years (range, 18-91 years), and the median Karnofsky Performance Status (KPS) was60. Patients at least 60 years old and at least 70 years old comprised 72% and43% of the study population, respectively.

Thesedata are in line with epidemiologic studies reporting a continuouslyincreasing rate in the elderly over the last decades, the study authorscommented.

Morethan 90% of patients were treated with high-dose methotrexate chemotherapy,including more than 80% of patients aged 80 years or older, although the dosewas more likely to be lower in the latter population.

Consolidationtherapy with WBRT or ASCT was received by 15% and 6% of patients, respectively,although the majority of these patients were younger than 60, with only 11% ofpatients aged 60 years or older receiving consolidation therapy.

Theobjective response rate (ORR) to first-line treatment was significantly higherin younger patients compared with older patients (73% vs 54%; P <.001), and ORRs for the overallpopulation and the population treated with consolidation therapy were 59% and92%, respectively.

Ata median follow-up of 44.4 months, the median overall survival (OS) for theoverall population was 25.3 months. Although the rates of 1-, 2-, and 5-year OSfor the overall population were 62%, 51%, and 38%, the 5-year OS rate for thosetreated with first-line high-dose chemotherapy followed by ASCT was 76%.

One-quarterof patients included in the study died within 6 months of primary CNS lymphomadiagnosis, and these patients were more likely to be older (P <.001) and to have a worse KPS atdiagnosis (P <.001). Cause ofdeath in this group was determined to be multifactorial in 44% of cases, andincluded impaired neurologic status due to lymphoma, complications (eg,infections), and/or treatment-related side effects.

MedianOS in patients 60 years or older at diagnosis of primary CNS lymphoma was 15.4months compared with 28.4 months in those younger than 60 years (P <.001).

Onmultivariate analysis, prognostic factors associated with longer OS includedage younger than 60 years (P <.001),KPS of 70 or higher at diagnosis (P<.001), female sex (P =.03), andresponse to first-line induction chemotherapy (P <.001).

Thefinding that age represents not only the strongest prognostic factor of thedisease, but also a major risk factor for severe treatment-relatedneurotoxicity, prompted the study authors to conclude that these resultsshould stimulate specific studies devoted to the elderly [with primary CNSlymphoma] to optimize the therapeutic management of this growing vulnerablepopulation.

Reference

Houillier C, Soussain C, Ghesquires H, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study [published online January 6, 2020]. Neurology. doi:10.1212/WNL.0000000000008900

View original post here:
Younger Age, Consolidation Therapy With Autologous SCT Associated With Improved OS in Patients With Primary CNS Lymphoma - Oncology Nurse Advisor

Cardio Round-up: Nanoparticles and Stem Cells in the Spotlight – DocWire News

This weeks Round-up looks to the future, as nanoparticles and stem cell-derived cardiac muscle cells get a closer look. More good news for lovers of yogurt, and a smelly but effective treatment for atherosclerosis as well.

Using stem cells extracted from the patients own blood and skin cells, this Japanese research team completed the first-in-human transplant of cardiac muscle cells derived from pluripotent stem cells. The team achieved this by reprogramming them, reverting them to their embryonic-like pluripotent initial state. I hope that (the transplant) will become a medical technology that will save as many people as possible, as Ive seen many lives that I couldnt save, Yoshiki Sawa, a professor in the Osaka University cardiovascular surgery unit, said in apress report.

Stem Cell-Derived Heart Muscle Transplanted Into Human for First Time: Researchers

Like something from a sci-fi horror novel, this team of researcher examined the role that nanoparticles that eat dead cells and stabilize atherosclerotic plaque may be able to play in the future of atherosclerosis treatment. We found we could stimulate the macrophages to selectively eat dead and dying cells these inflammatory cells are precursor cells toatherosclerosis that are part of the cause of heart attacks, one of the authors said in press release. We could deliver a small molecule inside the macrophages to tell them to begin eating again. The authors noted that after a single-cell RNA sequencing analysis, they observed that the prophagocytic nanotubes decreased inflammatory gene expression linked to cytokine and chemokine pathways in lesional macrophages, thereby treating the cell from the inside out.

Are Nanoparticles Potential Gamechangers for Treating Clogged Arteries?

In this large analysis of more than 120,000 individuals, the authors reported multivariable-adjusted hazard ratios (95% CI for all) for mortality were reduced in regular (more than four servings per week) consumers of yogurt, and there was an inverse relationship between regular consumption and cancer mortality as well as cardiovascular-related mortality in women. In our study, regular yogurt consumption was related to lower mortality risk among women, the authors wrote. Given that no clear doseresponse relation was apparent, this result must be interpreted with caution.

Yogurt Consumption Associated with Reduced Mortality Risk (Plus a Caveat)

This research teamlooked human microphages and compared them to dying cells in a dish. They observed that macrophages reclaim arginine and other amino acids when they eat dead cells, and then use an enzyme to convert arginine to putrescine. The putrescine, in return, activates a protein (Rac1) that causes the macrophage to eat more dead cells, suggesting to the authors that the problem of atherosclerosis may be, in part, a problem of putrescine. The findings, according to the accompanying press release, suggest that the compound could be use to potentially treat conditions with chronic inflammation, such as Alzheimers disease.

The Nose Knows: Pungent Compound Associated with Improvements in Atherosclerotic Plaque

Read the rest here:
Cardio Round-up: Nanoparticles and Stem Cells in the Spotlight - DocWire News

Now More Than Just Spine – PRNewswire

ATLANTA, Jan. 31, 2020 /PRNewswire/ --Spine Center Atlanta, founded in 1991 by James Chappuis, MD, FACS, welcomes two new physicians, Brett Rosenberg, MD and Brian Adams, MD. With their addition, Spine Center Atlanta expands its comprehensive patient care platform to include general orthopedic care and interventional pain management, bringing our unique, patient centric program to a wider range of patients.

Dr. Brett Rosenberg, certified by the American Board of Orthopaedic Surgery, earned his medical degree from Thomas Jefferson University Medical College, graduating cum laude. He went on to complete the orthopedic residency program at NYU Langone Hospital.

Dr. Rosenberg brings to Spine Center Atlanta his extensive experience in arthroscopic joint procedures specializing in shoulders and knees as well as total knee replacements, endoscopic carpal tunnel surgery, and fracture care.

Dr. Brian Adams, Spine Interventionalist, has earned a trio of board certifications including Anesthesiology, Interventional Pain Management, and Addiction Medicine. Dr. Adams received a master's degree in Biomedical Engineering from Colorado State University and a Doctorate of Medicine from The Medical College of Georgia followed by an internship and residency with the Department of Anesthesiology at The University of Texas Southwestern. Dr. Adams was recruited by his physician educators to remain for an additional year of advanced level fellowship training in interventional spine procedures and pain management.

When asked about his interventional pain management practice at Spine Center Atlanta, Doctor Adams shared, "So far my experience here has been amazing. We see a population of patients with diverse types and sources of pain, both acute and chronic. It is very rewarding that we are able to successfully treat our patients with state-of-the-art techniques and management."

Both recently appointed physicians' practices are aligned with the Spine Center Atlanta's commitment of, "Getting our patients back to play, back to work, and back to life!"

Beyond our newly expanded practice and treatment options, Spine Center Atlanta provides comprehensive ancillary services including physical therapy, cryotherapy, stem cell treatments, therapeutic massage, and aquatic therapy for patients in our five Georgia locations as well as providing e-consults and travel assistance for patients across the globe.

For more information about Doctors Chappuis, Rosenberg, and Adams and the latest news with Spine Center Atlanta, visit us at https://www.spineatl.com.

SOURCE Spine Center Atlanta

View post:
Now More Than Just Spine - PRNewswire

Does early relapse impact the outcomes of patients with mantle cell lymphoma (MCL)? – Lymphoma Hub

To address these unanswered questions, David A. Bond, The Ohio State University Hospital, Columbus, US, and colleagues conducted a retrospective analysis to evaluate the impact of early relapse on patient outcome in MCL. The data were presented during the 61st American Society of Hematology Meeting & Exposition, Orlando, US.1

Patients with MCL, treated at 12 North American medical centers between 20002017 were retrospectively identified (n= 1,168). In total, 711 patients were excluded from the analysis due to a lack of progression following frontline therapy, or a lack of follow-up data. The remaining patients (n= 457) who experienced relapse were split into three groups based on time to first relapse and treatment intensity*:

* Intensive treatment was defined as high-dose cytarabine-containing induction and/or autologous stem cell transplant (ASCT) in first complete remission (CR1)

Patients in the early relapse groups (PRF and POD24) were generally older (p< 0.001), with a higher frequency of known baseline risk factors including: presence of B symptoms (p< 0.001), a higher MCL International Prognostic Index (MIPI) score (p= 0.001), blastoid morphology (p< 0.001), a Ki67 > 30% (p< 0.001) and a complex karyotype (p= 0.001).

Median follow-up was 2.6 years in surviving patients. Patients who experienced early relapse (PRF and POD24) had a lower secondary median progression-free survival (PFS2) and overall survival (OS) compared to patients with POD> 24 (Table 1). In patients treated with intensive treatment, patients relapsing in < 24 months following induction had a poorer OS. However, OS was improved in patients with POD24 (and POD> 24) following a less intensive frontline treatment. PRF patients had the poorest outcomes.

Table 1. Patient outcomes by POD status

PRF

POD24

POD> 24

p value

Median PFS2 from first relapse, years (95% CI)

1 (0.41.3)

1 (0.81.4)

2.3 (1.83.2)

< 0.0001

OS from first relapse, years (95% CI)

1.3 (0.92.4)

3 (26.8)

8 (6.2NR)

< 0.0001

Patients treated with intensive frontline treatment

OS from first relapse, years (95% CI)

0.9 (0.43)

2 (1.13.4)

9.5 (4.8NR)

< 0.0001

Patients treated with less-intensive frontline treatment

OS from first relapse, years (95% CI)

2 (0.94.5)

6.8 (3.19.7)

10.5 (5.8NR)

< 0.0001

Univariable analysis identified factors associated with mortality (Table 2) which included POD status. Patients in the PRF and POD24 groups had an increased risk of mortality compared with the POD> 24 group.

Table 2. Factors significantly associated with survival in univariable analysis

Factor

Risk of mortality

HR

95% CI

p value

PRF status

Increased

3.77

2.475.77

< 0.001

POD24 status

Increased

2.12

1.532.94

0.002

B symptoms

Increased

1.42

1.021.96

0.036

High MIPI score

Increased

2.47

1.404.36

0.003

Blastoid morphology

Increased

1.93

1.282.91

0.002

Complex karyotype

Increased

2.21

1.124.36

0.022

Rituximab maintenance

Reduced

0.57

0.370.87

0.010

Study investigators conducted multivariable analysis to analyze whether the increased risk in early relapse was present, irrespective of baseline MIPI score and maintenance rituximab. A high MIPI score remained associated with increased risk of death (HR= 2.40; 95% CI, 1.284.50, p= 0.006) and maintenance rituximab was still associated with a reduced risk of death (HR= 0.29; 95% CI, 0.140.58, p< 0.001).

Significantly, early relapse remained a prognostic factor for poor OS:

Given that patients with PRF had the highest risk of early death, their subsequent outcomes were compared by type of second-line treatment. Second-line treatment was lenalidomide and/or bortezomib, chemo-immunotherapy (CIT) or BTK inhibitor (BTKi) (Table 3).

Type of second-line treatment was significant in PRF patients (p= 0.036), with BTKi treatment providing the longest median PFS2. OS was unaffected by second-line treatment (p= 0.546).

Table 3. PFS2 by second-line treatment in patients with PRF disease

Second-line treatment

Median PFS2, years

95% CI

BTKi

1.2

0.52.3

CIT

0.5

0.22.3

Lenalidomide and/or bortezomib

0.3

0.10.6

In this analysis of patients with MCL, a short duration of first remission was associated with an increased risk of death, irrespective of frontline therapy intensity. In patients receiving a less intensive frontline treatment, early mortality was lower in patients who relapsed between six and 24 months following frontline treatment. In patients who relapse very early, BTKi therapy may initially control the disease, but these responses are not durable and novel therapeutic approaches, such as chimeric antigen receptor (CAR) T-cell therapy, are required.

More here:
Does early relapse impact the outcomes of patients with mantle cell lymphoma (MCL)? - Lymphoma Hub

UAMS Professor to Present Relationships Among Food, Health, and Disease in Food Science Seminar – University of Arkansas Newswire

Photo Submitted

Dr. Mahendran Mahadevan, a professor in the Department of Obstetrics and Gynecology at the University of Arkansas for Medical Sciences, willspeakfrom 3-4 p.m. Monday, Feb.3, in Room D2 of the Food Science Building, 2650 N. Young Ave. His presentation, "Food, Health, and Disease,"is open to everyone.

Mahadevan's presentation will focus on how different types of food and beverages plays a role in human body's health defense systems (Angiogenesis, stem cells/regeneration, microbiome, DNA protection, and immunity). This basic biological knowledge related to foods will be useful for better understanding about the effects of foods on the prevention and management of human diseases.

Mahadevan's research interests include: 1) roles of genetics, obesity, nutrition, food supplements, nutraceuticals, physical activity and other environmental/life style factors on prevention/public health and maternal, fetal, and child health; 2) tissue banking; 3) embryo and stem cell culture/expansion (particularly culture medium/conditions); and 4) gene therapy and stem cell gene therapy particularly in cancer and genetic diseases.

Mahadevan received his Veterinary medicine degree in 1975 from University of Ceylon Peradeniya, Sri Lanka and his doctoral degree in Reproductive biology from Monash University, Australia in 1982. His academic experience includes faculty positions in the Department of Physiology, School of medicine at the University of Ceylon and in the Department of Obstetrics and Gynecology at the University of Arkansas for Medical Sciences.

Read more:
UAMS Professor to Present Relationships Among Food, Health, and Disease in Food Science Seminar - University of Arkansas Newswire

Genetic risk scores open a host of concerns and implications – The Daily Cardinal

A world where we can predict what traits and diseases that a baby will be born with is nearly upon us. With the expanding availability of genetic data, researchers in both universities and industry are trying to figure out the complicated relationship between our DNA and human health. For traits and diseases that reflect the interaction between many genetic and oftentimes environmental risk factors, these sorts of predictions are more difficult to make.

Scientists use genome-wide association studies with very large sample sizes to calculate polygenic scores, which correlate genetic factors with complex traits, like height or BMI, and risk for complex diseases, like heart disease or autism.

Almost everything you can think of is highly polygenic meaning [that] many, many, many genes or hundreds of thousands of genetic locations could be affecting [a complex trait], Jason Fletcher, a UW-Madison professor of public affairs studying some of the ethical, legal and social implications of genomic science, said.

Since an individuals genome generally does not change over the course of their lifetime, polygenic scores could offer an avenue for identifying individuals for specialized treatments or early interventions, Fletcher adds.

The positive case might be something like thinking about an instance where there is polygenic score for dyslexia and potentially being able to use a score like that very early in a child's life as a way of collecting individuals who might benefit from specific learning interventions, Fletcher said.

Intellectual disabilities and learning disabilities often go unnoticed for years, which can leave a child to struggle.

Lauren Schmitz, a UW-Madison assistant professor of public affairs, also notes that whereas for heart disease, preventative measures are viewed favorably, for intellectual disability the measures used to intervene would need to be carefully considered to avoid stigmatizing individuals.

Schmitz also stresses that although the science is moving fast, the predictive accuracy of these polygenic risk scores varies depending on the trait or disease in question. However, the for-profit, direct-to-consumer DNA testing industry is blurring the lines on what genomic science can say.

The way I see it, it's the next frontier in personalized things, Schmitz said. I think we're a culture that loves things that are personalized to us me and my experience and so I think the genome is the next marketing frontier.

For example, last November the biotech company Genomic Prediction claimed it could offer polygenic scores for traits including diabetes, heart disease and even IQ as an additional amenity for parents having children through in vitro fertilization. Currently, IVF clinics test fertilized embryos before they are implanted into a uterus to check for inherited genetic disease, like cystic fibrosis or Tays-Sachs disease, or for major chromosome abnormalities that can dramatically decrease the likelihood of a fetus being carried to term.

The announcement has been met with concern from scientists about the accuracy of these new preimplantation tests as well as the long-term effects of selecting on the basis of these traits.

There's all sorts of things where we don't even understand how these different mechanisms are operating and how they're correlated with other aspects of the genome, Schmitz said.

Measurements of intelligence like IQ tests are controversial, and as Angela Saini writes in Superior: The Return of Race Science, much of the work correlating educational attainment with genetics has direct ties to the vestiges of the eugenics movement in the early 20th century. Additionally, for many complex traits and diseases in combination with social and environmental factors at play, these polygenic scores are not necessarily an indication that the trait or disease will manifest.

We should be clear that the scores are not destiny, and there's an upper limit on how predictive it could be, Fletcher said.

Go here to see the original:
Genetic risk scores open a host of concerns and implications - The Daily Cardinal

"Mini Brains" Are Not like the Real Thing – Scientific American

The idea of scientists trying to grow brain tissue in a dish conjures up all sorts of scary mental pictures (cue the horror-movie music). But the reality of the research is quite far from that sci-fi visionand always will be, say researchers in the field. In fact, a leader in this area of research, Arnold Kriegstein of the University of California, San Francisco, says the reality does not measure up to what some scientists make it out to be.

In a paper published on January 29 in Nature, Kriegstein and his colleagues identified which genes were active in 235,000 cells extracted from 37 different organoids and compared them with 189,000 cells from normally developing brains. The organoidsat times called mini brains, to the chagrin of some scientistsare not a fully accurate representation of normal developmental processes, according to the study.

Brain organoids are made from stem cells that are transformed from one cell type to the another until they end up as neurons or other mature cells. But according to the Nature paper, they do not always fully complete this developmental process. Instead the organoids tend to end up with cells that have not fully transformed into new cell typesand they do not re-create the normal brains organizational structure. Psychiatric and neurodevelopmental conditionsincluding schizophrenia and autism, respectivelyand neurodegenerative diseases such as Alzheimers are generally specific to particular cell types and circuits.

Many of the organoid cells showed signs of metabolic stress, the study demonstrated. When the team transplanted organoid cells into mice, their identity became crisper, and they acted more like normal cells, Kriegstein says. This result suggests that the culture conditions under which such cells are grown does not match those of a normally developing brain, he adds. Cellular stress is reversible, Kriegstein says. If we can reverse it, were likely to see the identity of cells improve significantly at the same time.

Brain organoids are getting better at recapitulating the activities of small clusters of neurons, says Kriegstein, who is a professor of neurology and director of the Eli & Edythe Broad Center for Regeneration Medicine and Stem Cell Research at U.C.S.F. Scientists often make organoids from the cells of people with different medical conditions to better understand those conditions. But some scientists may have gone too far in making claims about insights they have derived from patient-specific brain organoids. Id be cautious about that, Kriegstein says. Some of those changes might reflect the abnormal gene expression of the cells and not actually reflect a true disease feature. So thats a problem for scientists to address.

A small ball of cells grown in a dish may be able to re-create some aspects of parts of the brain, but it is not intended to represent the entire brain and its complexity, several researchers have asserted. These organoids are no more sentient than brain tissue removed from a patient during an operation, one scientist has said.

Of course, models are never perfect. Although animal models have led to fundamental insights into brain development, researchers have sought out organoids, or organs-in-a-dish, precisely because of the limitations of extrapolating biological insights from another species to humans. Alzheimers has been cured hundreds of times in mice but never in us, for instance.

That said, the current models are already very useful in addressing some fundamental questions in human brain development, says Hongjun Song, a professor of neuroscience at the Perelman School of Medicine at the University of Pennsylvania, who was not involved in the new research. Using brain organoids, he adds, the Zika virus was recently shown to attack neural stem cells, causing a response that could explain why some babies exposed to Zika in utero develop unusually small brains.

Michael Nestor, a stem cell expert, who did not participate in the new study, says his own organoids are very helpful for identifying unusual activity in brain cells grown from people with autism. And he notes that they will eventually be useful for screening potential drugs.

Even though the models will always be a simplification, the organoid work remains crucial, says PaolaArlotta, chair of the department of stem cell and regenerative biology at Harvard University, who was also not involved in the Nature study. Neuropsychiatric pathologies and neurodevelopmental conditions are generally the result of a large number of genetic changes, which are too complex to be modeled in rodents, she says.

Sergiu Pasca, another leader in the field, says that the cellular stress encountered by Kriegstein and his team might actually be useful in some conditions, helping to create in a dish the kinds of conditions that lead to diseases of neurodegeneration, for instance. What I considerthe most exciting feature remains our ability to derive neural cells and glial cells in vitro, understanding their intrinsic program of maturation in a dish, says Pasca, an assistant professor at Stanford University, who was not part of the new paper.

The ability to improve cell quality when exposed to the environment of the mouse brain suggests that it may be possible to overcome some of the current limitations, Arlotta says. There is not yet a single protocol for making brain organoids in a lab, which may be for the best at this early stage of the field. Eventually, she says, scientists will optimize and standardize the conditions in which these cells are grown.

Arlotta, who is also the Golub Family Professor of Stem Cell and Regenerative Biology at Harvard, published a study last year in Nature showing that she and her colleagues canover a six-month periodmake organoids capable of reliablyincluding a diversity of cell types that are appropriate for the human cerebral cortex. She says it is crucial for organoid work to be done within an ethical framework. Arlotta is part of a federally funded team of bioethicists and scientists working together to ensure that such studies proceed ethically. The scientists educate the bioethicists on the state of the research, she says, and the ethicists inform the scientists about the implications of their work.

Nestor feels so strongly about the importance of linking science, policy and public awareness around stem cell research that he has put his own laboratory at the Hussman Institute for Autism on hold to accept a year-long science-and-technology-policyfellowship with the American Association for the Advancement of Science. He says he took the post to make sure the public and policy makers understand what they need to know about organoids and other cutting-edge science and to learn how to communicate about science with them.

One thing all of the scientists interviewed for this article agree on is that these brain organoids are not actual mini brains, and no one is trying to build a brain in a dish. Even as researchers learn to make more cell types and grow them in more realistic conditions, they will never be able to replicate the brains structure and complexity, Kriegstein says. The exquisite organization of a normal brain is critical to its function, he adds. Brains are still the most complicated structure that nature has ever created.

See the original post here:
"Mini Brains" Are Not like the Real Thing - Scientific American